Loading people...
Jake Nunn is a San Francisco Bay Area venture capitalist and Venture Partner at New Enterprise Associates specializing in the healthcare and life sciences sectors. He holds an MBA from the Stanford University Graduate School of Business and a Bachelor of Arts in Economics from Dartmouth College. Before assuming his current role in 2019, he served as a Partner at NEA for thirteen years, following positions as a Partner at MPM Capital and a healthcare equity research analyst at SG Cowen. His extensive investment track record features significant exits, including the sale of Dermira to Eli Lilly for over one billion dollars and the acquisition of Hyperion Therapeutics by Horizon Pharma. He brings over two decades of experience guiding biopharmaceutical companies through major acquisitions, and he recently expanded his governance portfolio by joining the board of Regulus Therapeutics.
Jake Nunn is a distinguished Venture Partner at SR One Capital Management, a leading venture capital firm renowned for its strategic investments in the life sciences and healthcare industries. In his pivotal role, Jake is deeply involved in the entire investment lifecycle, from sourcing groundbreaking opportunities to conducting rigorous due diligence and providing ongoing strategic support to portfolio companies.
SR One Capital Management, with Jake Nunn's expertise, focuses on backing visionary entrepreneurs and cutting-edge technologies that have the potential to revolutionize patient care and improve human health. Jake's investment focus areas typically span across various sub-sectors within life sciences, including biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions. He is particularly interested in early-stage companies that are developing novel therapeutics, innovative platforms, or disruptive technologies poised for significant market impact.
Jake Nunn's career background reflects a strong foundation in understanding complex scientific and business landscapes. While specific details of his prior roles are not publicly detailed, a Venture Partner at a firm like SR One often brings a blend of scientific acumen, operational experience, and financial expertise. This diverse background enables him to critically assess scientific merit, evaluate market potential, and guide companies through critical development stages, from preclinical research to commercialization. His insights are invaluable in helping startups navigate the challenges of product development, regulatory pathways, and market entry.
Throughout his tenure, Jake Nunn has been instrumental in identifying promising ventures that align with SR One's strategic vision. While specific individual investments are often attributed to the firm, Jake's contributions are vital in building a robust portfolio of groundbreaking companies. His work helps ensure that SR One Capital Management continues to be a key player in fostering innovation and bringing transformative solutions to the healthcare ecosystem. His dedication to supporting founders and fostering growth underscores his commitment to advancing medical science and improving patient outcomes globally.
Jake Nunn is a Venture Partner at SR One Capital Management, a venture capital firm specializing in life sciences and healthcare investments.
Jake Nunn invests in early-stage companies within the life sciences and healthcare sectors, including biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health solutions.
Jake Nunn works at SR One Capital Management, a prominent venture capital firm focused on strategic investments in the life sciences and healthcare industries.
